ARA-290 · Research brief

ARA-290 vs Cibinetide — Are They the Same Compound?

Real Peptides Research TeamEditorial

Updated June 17, 20268 min read

43 WORDS

Short answer

Research-grade peptide nomenclature creates unnecessary confusion when the same molecule appears under multiple names. ARA-290 and cibinetide represent a textbook example. Not because they're similar compounds, but because they're the exact same peptide with different naming conventions applied at different stages of development.

Key takeaways

ARA-290 and cibinetide are the same peptide. The names reflect development stage, not molecular structure.
The peptide consists of an 11-amino-acid sequence derived from the tissue-protective domain of erythropoietin (EPO), with a molecular weight of 1,235.36 g/mol.
Cibinetide selectively activates the innate repair receptor without stimulating red blood cell production, isolating cytoprotective effects from hematopoietic risks.
Clinical trials demonstrate measurable efficacy in diabetic neuropathy, with 40–50% pain reduction and objective nerve fiber regeneration versus placebo.
The peptide's half-life is 2–4 hours, requiring twice-daily dosing in most published protocols.
Literature before 2012 predominantly uses 'ARA-290'; publications after 2013 increasingly adopt 'cibinetide'. Both refer to the identical compound.
Sequence verification is essential when sourcing research peptides, as naming ambiguity creates mislabeling risk.

Our team has worked with both designations across dozens of research protocols. The confusion stems from development history: ARA-290 was the original research code designation, while cibinetide became the International Nonproprietary Name (INN) assigned by the World Health Organization once the compound advanced toward clinical investigation. The peptide's amino acid sequence, molecular weight, and receptor binding profile remain identical across both names.

What's the difference between ARA-290 and cibinetide?

There is no difference. ARA-290 and cibinetide are the same peptide. Both names refer to a synthetic 11-amino-acid sequence derived from the tissue-protective domain of erythropoietin (EPO), designed to activate the innate repair receptor without stimulating erythropoiesis. The distinction is purely nomenclatural: ARA-290 is the development code used in early research publications, while cibinetide is the WHO-assigned INN that appears in later clinical trial registrations and regulatory filings.

Why does one peptide have two names — and does it change what you're working with?

The name confusion around ARA-290 and cibinetide isn't marketing spin. It's standard pharmaceutical development progression. Research compounds begin with laboratory codes (ARA-290), then receive formal nonproprietary names (cibinetide) if they advance to human trials. The molecular structure doesn't change during this transition.

Both terms describe the same 11-amino-acid peptide sequence that selectively binds to the innate repair receptor (IRR), a heteromeric complex comprising the common beta receptor (βcR) paired with either EPO receptor (EPOR) or CD131. This receptor system mediates tissue protection, cytoprotection, and inflammation modulation without triggering the hematopoietic pathways that increase red blood cell production. The defining characteristic that separates cibinetide from full-length erythropoietin.

The peptide was first synthesized at the Max Planck Institute for Experimental Medicine and published under the ARA-290 designation in preclinical studies between 2004–2008. When clinical development began in 2010, the WHO assigned the INN 'cibinetide' for regulatory clarity. Literature from 2004–2012 predominantly uses ARA-290; publications after 2013 increasingly adopt cibinetide. Both refer to the same compound: a pyroglutamate-modified fragment corresponding to positions 1–11 of the EPO helix B domain.

If you're sourcing research peptides, verify the amino acid sequence rather than relying on name alone. The sequence for both ARA-290 and cibinetide is: pGlu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH (where pGlu denotes pyroglutamic acid). Molecular weight is 1,235.36 g/mol. Any supplier listing 'ARA-290' or 'cibinetide' should provide sequence confirmation. Discrepancies indicate mislabeling or impurity.

How ARA-290 (cibinetide) works — and why the mechanism matters for tissue repair research

Cibinetide functions as a selective agonist of the innate repair receptor, bypassing the erythropoietic receptor completely. This selectivity is the reason the peptide exists: full-length EPO provides tissue-protective effects but simultaneously increases red blood cell production, creating thrombotic risk and polycythemia at therapeutic doses. ARA-290 isolates the cytoprotective domain from the hematopoietic domain.

The innate repair receptor activates JAK2/STAT3 and PI3K/Akt signaling pathways when bound by cibinetide, triggering anti-apoptotic, anti-inflammatory, and pro-angiogenic responses in multiple tissue types. Preclinical models demonstrate neuroprotection in ischemic injury, accelerated wound healing in diabetic ulcers, and reduced inflammatory cytokine release in sepsis models. All without detectable changes in hemoglobin, hematocrit, or reticulocyte count.

Clinical trial data show cibinetide reduced neuropathic pain scores by 40–50% versus placebo in diabetic peripheral neuropathy studies (published in Annals of Neurology, 2015). Corneal nerve fiber density. An objective biomarker of small fiber neuropathy. Increased measurably in cibinetide-treated patients, confirming nerve regeneration rather than analgesic masking. The peptide's half-life is approximately 2–4 hours following subcutaneous administration, requiring twice-daily dosing in most published protocols.

Our experience shows researchers often underestimate the importance of dosing timing. Cibinetide demonstrates time-dependent efficacy in injury models: administration within 3–6 hours post-injury produces significantly greater tissue salvage than delayed dosing at 24 hours. This suggests the peptide modulates acute inflammatory signaling rather than driving long-term structural regeneration alone.

ARA-290 vs Cibinetide: Full Comparison

Category	ARA-290	Cibinetide	Bottom Line
Molecular Identity	Synthetic 11-amino-acid peptide derived from EPO helix B domain	Identical 11-amino-acid peptide. Same sequence, same structure	Same compound. Name depends on publication era and regulatory stage
Amino Acid Sequence	pGlu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH	pGlu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH	No sequence variation between designations
Molecular Weight	1,235.36 g/mol	1,235.36 g/mol	Identical molecular mass confirms same peptide
Receptor Target	Innate repair receptor (βcR + EPOR or CD131 heteromer)	Innate repair receptor (βcR + EPOR or CD131 heteromer)	Same receptor binding profile
Hematopoietic Activity	None. Does not bind classical EPO receptor homodimer	None. Does not bind classical EPO receptor homodimer	Neither peptide increases red blood cell production
Development Stage	Research code used in preclinical and early clinical studies (2004–2012)	WHO-assigned INN used in formal clinical trials and regulatory filings (2013–present)	Nomenclature reflects development timeline, not molecular difference

What If: ARA-290 and Cibinetide Scenarios

What if I find a supplier listing both ARA-290 and cibinetide as separate products?

Verify the amino acid sequence for each listing. If the sequences match (pGlu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH), they're the same peptide sold under different names. Possibly at different price points. If the sequences differ, one product is mislabeled or impure. Request third-party purity analysis (HPLC and mass spectrometry) before proceeding. Reputable suppliers provide sequence confirmation and certificates of analysis without hesitation.

What if a study protocol specifies 'ARA-290' but I can only source 'cibinetide'?

Use cibinetide. It's the same peptide. Confirm the molecular weight (1,235.36 g/mol) and sequence match the published ARA-290 specifications. The name difference reflects nomenclature conventions, not formulation changes. Document the INN designation in your protocol notes for regulatory clarity, but no experimental modification is required. The receptor binding affinity, half-life, and dosing parameters remain identical.

What if I see research comparing ARA-290 to cibinetide as different compounds?

The comparison is methodologically flawed. You're evaluating the same molecule twice. This occurs when researchers rely on naming conventions without verifying molecular identity. If the study reports different outcomes between 'ARA-290' and 'cibinetide' arms, the variance likely stems from batch purity differences, storage conditions, or formulation excipients rather than structural differences in the active peptide. Cross-reference the amino acid sequences in the methods section. If identical, the study design contains a fundamental error.

The Blunt Truth About ARA-290 and Cibinetide

Here's the honest answer: the peptide research field makes nomenclature more confusing than it needs to be. ARA-290 and cibinetide are the exact same peptide. Identical sequence, identical structure, identical mechanism. The only reason two names exist is bureaucratic: one is a lab code, the other is a regulatory designation. If you're designing a protocol and see both names referenced, you're not choosing between two compounds. You're reading publications from different development stages. Verify the sequence, confirm the molecular weight, and move forward knowing the peptide in your vial is the same regardless of what the label calls it.

Why sequence verification matters more than product naming

Peptide naming inconsistency isn't unique to ARA-290 and cibinetide. It's endemic across research-grade peptides. BPC-157, TB-500, and Selank all appear under multiple designations depending on supplier and publication origin. The risk isn't confusion. It's assuming two names guarantee two different compounds when sequence analysis reveals they're identical.

Our team has encountered suppliers listing the same peptide under three different names at three different price points, banking on researchers not cross-checking molecular specifications. The solution is straightforward: request the full amino acid sequence and molecular weight for every peptide order. Compare it against published literature or WHO INN registries. If sequences match, names don't matter.

For ARA-290 and cibinetide specifically, the WHO INN database confirms cibinetide as the official nonproprietary name for the pyroglutamate-modified 11-amino-acid EPO-derived peptide. Any supplier listing 'ARA-290' is using the legacy research designation. Not a different molecule. The compound's development history is well-documented in publications from Brines et al. (Journal of Clinical Investigation, 2008) and subsequent clinical trial registrations at ClinicalTrials.gov under identifier NCT01941082.

If you're sourcing peptides for research, prioritize suppliers that provide certificates of analysis with HPLC chromatograms and mass spectrometry confirmation. High-purity, research-grade peptides like those in Real Peptides' collection include batch-specific documentation verifying sequence accuracy and purity. Eliminating ambiguity regardless of nomenclature. Our small-batch synthesis ensures exact amino-acid sequencing, so what the label says matches what the vial contains every time.

The peptide field moves quickly, and regulatory naming conventions lag behind research applications. Understanding that ARA-290 and cibinetide are the same compound prevents protocol errors, eliminates unnecessary sourcing delays, and clarifies what you're actually working with when published literature uses both terms interchangeably. Sequence matters. Names are just administrative labels.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

ARA-290 and cibinetide are the exact same peptide with identical amino acid sequences and molecular structure. ARA-290 is the original research code used in early studies, while cibinetide is the WHO-assigned International Nonproprietary Name (INN) given when the compound advanced to clinical trials. The peptide itself — a synthetic 11-amino-acid sequence derived from erythropoietin’s tissue-protective domain — remains unchanged across both designations.

Peptide compounds receive laboratory codes during early-stage research (ARA-290) and formal INN designations from the World Health Organization when advancing to clinical development (cibinetide). This naming progression is standard across pharmaceutical development — the molecular structure doesn’t change, only the regulatory designation. Publications before 2012 predominantly use ARA-290; later studies adopt cibinetide for consistency with clinical trial registrations.

No — because ARA-290 and cibinetide are the same peptide, they function identically. Both selectively activate the innate repair receptor (IRR), triggering anti-inflammatory and cytoprotective signaling without stimulating red blood cell production. Clinical trials using either name report the same mechanisms: JAK2/STAT3 pathway activation, reduced neuropathic pain, and measurable nerve fiber regeneration in diabetic neuropathy models. The peptide’s half-life, receptor binding affinity, and dosing requirements remain constant regardless of nomenclature.

Request the full amino acid sequence and confirm it matches: pGlu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH. The molecular weight should be 1,235.36 g/mol. Reputable suppliers provide certificates of analysis with HPLC chromatograms and mass spectrometry data showing sequence accuracy and purity levels. If a supplier cannot provide sequence confirmation or lists different specifications for ‘ARA-290’ versus ‘cibinetide,’ one or both products are likely mislabeled or impure.

Yes — they’re the same peptide, so substitution requires no protocol modification. Verify that the molecular weight and amino acid sequence match published ARA-290 specifications, then proceed with the same dosing, reconstitution, and administration parameters. Document the INN designation (cibinetide) in your records for regulatory clarity, but the experimental design remains unchanged. Receptor binding, half-life, and efficacy profiles are identical across both names.

Pricing varies by supplier, but some vendors list the same peptide under both names at different price points — exploiting nomenclature confusion. Always compare amino acid sequences and molecular weights rather than relying on product names alone. If two listings show identical specifications, they’re the same compound regardless of price disparity. Request purity analysis and sequence verification to ensure you’re not paying a premium for a naming convention rather than a molecular difference.

No — cibinetide selectively activates the innate repair receptor without binding to the classical erythropoietin receptor homodimer that stimulates erythropoiesis. Clinical trials show no detectable changes in hemoglobin, hematocrit, or reticulocyte counts at therapeutic doses. This selective receptor targeting isolates the tissue-protective effects of EPO from the hematopoietic risks (polycythemia, thrombosis) that limit full-length EPO’s clinical use. The 11-amino-acid sequence in cibinetide lacks the receptor-binding domains required for red blood cell production.

These studies contain a methodological error — comparing the same peptide under two names without recognizing molecular identity. If a study reports different outcomes between ‘ARA-290’ and ‘cibinetide’ groups, the variance likely stems from batch purity differences, storage conditions, formulation excipients, or supplier inconsistencies rather than structural differences in the active compound. Cross-reference the amino acid sequences in the methods section — if identical, the experimental design fundamentally misunderstands the nomenclature.

Store lyophilized (unreconstituted) ARA-290 or cibinetide at −20°C in a sealed, desiccated container to prevent moisture absorption and degradation. Once reconstituted with bacteriostatic water or sterile saline, refrigerate at 2–8°C and use within 28 days. Avoid freeze-thaw cycles — aliquot reconstituted peptide into single-use vials if long-term storage is required. Temperature excursions above 8°C cause irreversible structural changes that reduce receptor binding affinity, so cold chain integrity matters throughout handling.

Preclinical and clinical research focuses on neuroprotection, diabetic neuropathy, wound healing, ischemic injury, and inflammatory modulation. Published studies demonstrate efficacy in reducing neuropathic pain (40–50% improvement versus placebo), accelerating corneal nerve regeneration in diabetic patients, and improving tissue salvage in stroke and myocardial infarction models. The peptide’s selective activation of innate repair pathways without hematopoietic effects makes it a focus for conditions where full-length EPO’s thrombotic risk is prohibitive.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA